Rocuronium 0.8 — Competitive Intelligence Brief

Rocuronium 0.8 (Rocuronium 0.8) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesiology.

phase 3 Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesiology Small molecule

Target snapshot

Rocuronium 0.8 (Rocuronium 0.8) — Ain Shams University. Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits nicotinic acetylcholine receptors at the neuromuscular junction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rocuronium 0.8 TARGET	Rocuronium 0.8	Ain Shams University	phase 3	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Varenicline (VAR)	Varenicline (VAR)	University of Oklahoma	marketed	Nicotinic receptor partial agonist	Alpha-4 beta-2 nicotinic acetylcholine receptor
Varenicline (Champix)	Varenicline (Champix)	University of British Columbia	marketed	Nicotinic receptor partial agonist	Alpha-4 beta-2 nicotinic acetylcholine receptor
Varenicline Pill	Varenicline Pill	National Institute on Drug Abuse (NIDA)	marketed	Nicotinic receptor partial agonist	Alpha-4 beta-2 nicotinic acetylcholine receptor
Nicotine replacement therapy sampling	Nicotine replacement therapy sampling	The University of Hong Kong	marketed	Nicotinic receptor agonist	Nicotinic acetylcholine receptors
NMBA - cisatracurium	NMBA - cisatracurium	CHU de Reims	marketed	Non-depolarizing neuromuscular blocking agent (NMBA)	Nicotinic acetylcholine receptor at the neuromuscular junction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

1. University Hospital, Antwerp · 3 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
5. Federal University of São Paulo · 1 drug in this class
6. Korea University Guro Hospital · 1 drug in this class
7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
8. Ostfold Hospital Trust · 1 drug in this class
9. St. Antonius Hospital · 1 drug in this class
10. CHU de Reims · 1 drug in this class